EP Patent

EP1883302A4 — Jak kinase inhibitors and their uses

Assigned to Rigel Pharmaceuticals Inc · Expires 2009-05-20 · 17y expired

What this patent protects

The present disclosure provides 2,4-pyrimidinediamine compounds that selectively inhibit JAK kinase as compared to Syk kinase and various methods of using the JAK-selective compounds.

USPTO Abstract

The present disclosure provides 2,4-pyrimidinediamine compounds that selectively inhibit JAK kinase as compared to Syk kinase and various methods of using the JAK-selective compounds.

Drugs covered by this patent

Patent Metadata

Patent number
EP1883302A4
Jurisdiction
EP
Classification
—
Expires
2009-05-20
Drug substance claim
No
Drug product claim
No
Assignee
Rigel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.